modelD05AX01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | FumaricAcid | |
| ATC code: | D05AX01 | route: | oral |
| compartments: | 1 | |
| dosage: | 120 | mg |
| volume of distribution: | 50 | L |
| clearance: | 50 | L/h |
| other parameters in model implementation | ||
Fumaric acid is a naturally occurring organic acid that has been used as a medicinal product in the form of its ester derivatives (dimethyl fumarate or DMF) for the treatment of psoriasis and multiple sclerosis. Fumaric acid itself is generally not used directly as a pharmaceutical agent. The drug indicated by ATC code D05AX01 refers specifically to the fumarates used in dermatology, mainly for moderate to severe plaque psoriasis, and may include salts like calcium, magnesium, and zinc fumarate. Fumaric acid and its esters are approved in several European countries for psoriasis and DMF is approved globally for multiple sclerosis.
Pharmacokinetics
No direct human pharmacokinetic data available for fumaric acid as an isolated compound administered as a drug. Most pharmacokinetic studies pertain to its ester forms (i.e., dimethyl fumarate). Thus, below parameters are estimated or inferred.
References
Shimizu, R, et al., & Kubota, R (2023). A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations. Clinical drug investigation 43(10) 785–797. DOI:10.1007/s40261-023-01309-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/37798608
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)